secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001159036-24-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q1 revenue up 21% to $196M; non-GAAP EPS $0.79, net income $76.8M
--------------------------------------------------------------------------

- Revenue $195.9M (+21% YoY), driven by 21% royalty growth to $120.6M from DARZALEX and Phesgo.
- GAAP diluted EPS $0.60; non-GAAP diluted EPS $0.79, vs $0.29 and $0.47 in Q1 2023.
- Adjusted EBITDA $115.7M, up 56% from $74.3M; cash and securities $463.5M at quarter end.
- Reiterated FY 2024 guidance: revenue $915-985M, adjusted EBITDA $535-585M, non-GAAP EPS $3.55-$3.90.
- New $750M share repurchase program announced; partner milestones include $15M from BMS for nivolumab SC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/0001159036-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/halo-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001159036-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer